207 related articles for article (PubMed ID: 27167227)
1. Health care providers' support of patients' autonomy, phosphate medication adherence, race and gender in end stage renal disease.
Umeukeje EM; Merighi JR; Browne T; Wild M; Alsmaan H; Umanath K; Lewis JB; Wallston KA; Cavanaugh KL
J Behav Med; 2016 Dec; 39(6):1104-1114. PubMed ID: 27167227
[TBL] [Abstract][Full Text] [Related]
2. Self-Motivation Is Associated With Phosphorus Control in End-Stage Renal Disease.
Umeukeje EM; Merighi JR; Browne T; Victoroff JN; Umanath K; Lewis JB; Ikizler TA; Wallston KA; Cavanaugh K
J Ren Nutr; 2015 Sep; 25(5):433-9. PubMed ID: 25912398
[TBL] [Abstract][Full Text] [Related]
3. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.
Chiu YW; Teitelbaum I; Misra M; de Leon EM; Adzize T; Mehrotra R
Clin J Am Soc Nephrol; 2009 Jun; 4(6):1089-96. PubMed ID: 19423571
[TBL] [Abstract][Full Text] [Related]
4. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
5. Medication beliefs are associated with phosphate binder non-adherence in hyperphosphatemic haemodialysis patients.
Wileman V; Farrington K; Wellsted D; Almond M; Davenport A; Chilcot J
Br J Health Psychol; 2015 Sep; 20(3):563-78. PubMed ID: 25209368
[TBL] [Abstract][Full Text] [Related]
6. The impact of nurse-led education on haemodialysis patients' phosphate binder medication adherence.
Sandlin K; Bennett PN; Ockerby C; Corradini AM
J Ren Care; 2013 Mar; 39(1):12-8. PubMed ID: 23432740
[TBL] [Abstract][Full Text] [Related]
7. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
8. Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis.
Hung KY; Liao SC; Chen TH; Chao MC; Chen JB
Ther Apher Dial; 2013 Feb; 17(1):72-7. PubMed ID: 23379497
[TBL] [Abstract][Full Text] [Related]
9. Interventional study to improve adherence to phosphate binder treatment in dialysis patients.
Hjemås BJ; Bøvre K; Mathiesen L; Lindstrøm JC; Bjerknes K
BMC Nephrol; 2019 May; 20(1):178. PubMed ID: 31101020
[TBL] [Abstract][Full Text] [Related]
10. Daily dietary phosphorus intake variability and hemodialysis patient adherence to phosphate binder therapy.
Tao X; Zhang H; Yang Y; Zhang C; Wang M
Hemodial Int; 2019 Oct; 23(4):458-465. PubMed ID: 31328873
[TBL] [Abstract][Full Text] [Related]
11. Provider Attitudes and Support of Patients' Autonomy for Phosphate Binder Medication Adherence in ESRD.
Umeukeje EM; Osman R; Nettles AL; Wallston KA; Cavanaugh KL
J Patient Exp; 2020 Oct; 7(5):708-712. PubMed ID: 33294605
[TBL] [Abstract][Full Text] [Related]
12. Understanding the associations between modifying factors, individual health beliefs, and hemodialysis patients' adherence to a low-phosphorus diet.
Elliott JO; Ortman C; Almaani S; Lee YH; Jordan K
J Ren Nutr; 2015 Mar; 25(2):111-20. PubMed ID: 25282006
[TBL] [Abstract][Full Text] [Related]
13. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
[TBL] [Abstract][Full Text] [Related]
14. Associations with Wellbeing and Medication Adherence in Young Adults Receiving Kidney Replacement Therapy.
Hamilton AJ; Caskey FJ; Casula A; Inward CD; Ben-Shlomo Y
Clin J Am Soc Nephrol; 2018 Nov; 13(11):1669-1679. PubMed ID: 30327297
[TBL] [Abstract][Full Text] [Related]
15. Patient-Reported Factors Associated With Poor Phosphorus Control in a Maintenance Hemodialysis Population.
Joson CG; Henry SL; Kim S; Cheung MY; Parab P; Abcar AC; Jacobsen SJ; Morisky DE; Sim JJ
J Ren Nutr; 2016 May; 26(3):141-8. PubMed ID: 26614738
[TBL] [Abstract][Full Text] [Related]
16. Choosing not to take phosphate binders: the role of dialysis patients' medication beliefs.
Wileman V; Chilcot J; Norton S; Hughes L; Wellsted D; Farrington K
Nephron Clin Pract; 2011; 119(3):c205-13. PubMed ID: 21832846
[TBL] [Abstract][Full Text] [Related]
17. Modeled Daily Ingested, Absorbed and Bound Phosphorus: New Measures of Mineral Balance in Hemodialysis Patients.
Kapoian T; Khalil S; O'Mara NB; Brink DM; Daugirdas JT
Am J Nephrol; 2019; 49(5):368-376. PubMed ID: 30939469
[TBL] [Abstract][Full Text] [Related]
18. Hyperphosphataemia: treatment options.
Malberti F
Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
[TBL] [Abstract][Full Text] [Related]
19. Hyperphosphatemia is associated with overt proteinuria in non-diabetic patients with late-stage chronic kidney disease: a cross-sectional study.
Yap YS; Chi WC; Lin CH; Wu YW; Liu YC
Int Urol Nephrol; 2013 Feb; 45(1):163-72. PubMed ID: 22467089
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]